Tarcocimab tedromer is under clinical development by Kodiak Sciences and currently in Phase III for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData, Phase III drugs for ...

Faricimab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData, Phase II drugs for ...

Diabetic patients were categorised into non-diabetic retinopathy (without diabetic retinopathy), non-proliferative diabetic retinopathy (NPDR), and proliferative diabetic retinopathy (PDR) subgroups ...

Signs of diabetic retinopathy were found in 24 people (21% of the diabetic population). Retinopathy changes were graded as mild to moderate non-proliferative retinopathy (NPDR) in 40 eyes (18 people), ...

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was ...

A case report demonstrates independent effect of GLP-1 receptor agonist.

He added that the totality of the data in non-proliferative diabetic retinopathy suggests clinical activity at "certain doses" and supports further clinical evaluation of the drug in this indication.

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...

(NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina experience, outlined exceptional clinical progress across its registrational program for ...

DR was graded according to early Treatment Diabetic Retinopathy (ETDRS ... (70.35%), which included 34 patients (17.1%) with mild non proliferative DR (NPDR), 34 patients (17.1%) with moderate ...

The 1-year results from the HELIOS Trial that evaluated the investigational intravitreal Axitinib implant (OTX-TKI, Ocular Therapeutix) for the treatment of non-proliferative diabetic retinopathy ...